{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:09:11Z","timestamp":1793956151841,"version":"4.8.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Leibniz Award"],"award-info":[{"award-number":["Leibniz Award"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1755 CASCAID"],"award-info":[{"award-number":["CRC 1755 CASCAID"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04430-6","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:02:08Z","timestamp":1779354128000},"page":"2007-2016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Resetting autoimmune disease with CAR cell therapies"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-118X","authenticated-orcid":false,"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4430_CR1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526\u20131533 (2003).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard-2024-225727","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett, G., Nagy, G., Kr\u00f6nke, G. & Mielenz, D. B-cell depletion in autoimmune diseases. Ann. Rheum. Dis. 83, 1409\u20131420 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR3","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","volume":"192","author":"LG Barnett","year":"2014","unstructured":"Barnett, L. G. et al. B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J. Immunol. 192, 3607\u20133617 (2014).","journal-title":"J. Immunol."},{"key":"4430_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","volume":"28","author":"M Uzzan","year":"2022","unstructured":"Uzzan, M. et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat. Med. 28, 766\u2013779 (2022).","journal-title":"Nat. Med."},{"key":"4430_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos, A. E. et al. Anti-Integrin \u03b1v\u03b26 Autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164, 619\u2013629 (2023).","journal-title":"Gastroenterology"},{"key":"4430_CR6","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","volume":"178","author":"M Duddy","year":"2007","unstructured":"Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B-cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092\u20136099 (2007).","journal-title":"J. Immunol."},{"key":"4430_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser, E. C. & Mauri, C. Regulatory B-cells: origin, phenotype, and function. Immunity 42, 607\u2013612 (2015).","journal-title":"Immunity"},{"key":"4430_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628\u2013639 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471\u20131483 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35\u201347 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR11","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"4430_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport, A. J. et al. CAR-T-cells inflict sequential killing of multiple tumor target cells. Cancer Immunol. Res. 3, 483\u2013494 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"4430_CR14","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.trim.2022.101726","volume":"75","author":"SS Mujtahedi","year":"2022","unstructured":"Mujtahedi, S. S. et al. Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture. Transpl. Immunol. 75, 101726 (2022).","journal-title":"Transpl. Immunol."},{"key":"4430_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero, J. et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin. Cytom. 90, 61\u201372 (2016).","journal-title":"Cytometry B Clin. Cytom."},{"key":"4430_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"4430_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-Cell therapy in autoimmune disease \u2013 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR18","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).","journal-title":"Sci. Transl. Med."},{"key":"4430_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"IC Nicholson","year":"1997","unstructured":"Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34, 1157\u20131165 (1997).","journal-title":"Mol. Immunol."},{"key":"4430_CR21","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR22","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.jaut.2025.103489","volume":"157","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study. J. Autoimmun. 157, 103489 (2025).","journal-title":"J. Autoimmun."},{"key":"4430_CR23","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng, J. et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3725\u20133736 (2025).","journal-title":"Nat. Med."},{"key":"4430_CR24","doi-asserted-by":"publisher","first-page":"e001742","DOI":"10.1136\/lupus-2025-001742","volume":"12","author":"JM Gerber","year":"2025","unstructured":"Gerber, J. M. et al. Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis. Lupus Sci. Med. 12, e001742 (2025).","journal-title":"Lupus Sci. Med."},{"key":"4430_CR25","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.eclinm.2025.103229","volume":"83","author":"J Shu","year":"2025","unstructured":"Shu, J. et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. EClinicalMedicine 83, 103229 (2025).","journal-title":"EClinicalMedicine"},{"key":"4430_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117\u20131120 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth, J. et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 7, 83\u201393 (2025).","journal-title":"Lancet Rheumatol."},{"key":"4430_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt, W. et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann. Rheum. Dis. 83, 543\u2013546 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815\u2013818 (2023).","journal-title":"Lancet"},{"key":"4430_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard-2024-226437","volume":"84","author":"M Lidar","year":"2025","unstructured":"Lidar, M. et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann. Rheum. Dis. 84, 370\u2013372 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597\u20131598 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR32","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou, I. et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann. Rheum. Dis. 84, e4\u2013e7 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR33","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","volume":"188","author":"C Qin","year":"2025","unstructured":"Qin, C. et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell 188, 6414\u20136423 (2025).","journal-title":"Cell"},{"key":"4430_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5, 550\u2013558 (2024).","journal-title":"Med"},{"key":"4430_CR35","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A., Hegelmaier, T. & Wolleschak, D. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"4430_CR36","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","volume":"271","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report. J. Neurol. 271, 4655\u20134659 (2024).","journal-title":"J. Neurol."},{"key":"4430_CR37","doi-asserted-by":"publisher","first-page":"103621","DOI":"10.1016\/j.eclinm.2025.103621","volume":"90","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial. EClinicalMedicine 90, 103621 (2025).","journal-title":"EClinicalMedicine"},{"key":"4430_CR38","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/acn3.70167","volume":"12","author":"N Chahin","year":"2025","unstructured":"Chahin, N. et al. Durability of response to B-cell maturation antigen-directed mRNA cell therapy in myasthenia gravis. Ann. Clin. Transl. Neurol. 12, 2358\u20132366 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4430_CR39","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte, J. et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron 112, 1757\u20131763 (2024).","journal-title":"Neuron"},{"key":"4430_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin, C. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct. Target. Ther. 8, 5 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"4430_CR41","doi-asserted-by":"publisher","first-page":"e2403227121","DOI":"10.1073\/pnas.2403227121","volume":"121","author":"S Faissner","year":"2024","unstructured":"Faissner, S. et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc. Natl Acad. Sci. USA 121, e2403227121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4430_CR42","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.medj.2025.100776","volume":"6","author":"T Hegelmaier","year":"2025","unstructured":"Hegelmaier, T. et al. Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. Med 6, 100776 (2025).","journal-title":"Med"},{"key":"4430_CR43","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJMc2508023","volume":"393","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis. N. Engl. J. Med. 393, 1239\u20131241 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","volume":"405","author":"K Trautmann-Grill","year":"2025","unstructured":"Trautmann-Grill, K. et al. Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells. Lancet 405, 25\u201328 (2025).","journal-title":"Lancet"},{"key":"4430_CR45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li, M. et al. Anti-CD19 CAR T Cells in refractory immune thrombocytopenia of SLE. N. Engl. J. Med. 391, 376\u2013378 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR46","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau, T. et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403, 1627\u20131630 (2024).","journal-title":"Lancet"},{"key":"4430_CR47","first-page":"1629","volume":"390","author":"F De Benedetti","year":"2024","unstructured":"De Benedetti, F., Diomedi Camassei, F. & Locatelli, F. CAR T-cell therapy in autoimmune disease. N. Engl. J. Med. 390, 1629 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR48","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai, R. et al. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 76, 1560\u20131565 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"4430_CR49","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He, X. et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun. Rev. 24, 103692 (2025).","journal-title":"Autoimmun. Rev."},{"key":"4430_CR50","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41591-025-04191-8","volume":"32","author":"M Becilli","year":"2026","unstructured":"Becilli, M. et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nat. Med. 32, 1105\u20131117 (2026).","journal-title":"Nat. Med."},{"key":"4430_CR51","unstructured":"Muller, F. et al. Safety and preliminary efficacy of zorpocabtagene-autoleucel in systemic autoimmune diseases. Nat. Med. (2026, in press)."},{"key":"4430_CR52","first-page":"53","volume":"13","author":"Y Mao","year":"2025","unstructured":"Mao, Y. et al. Bicistronic-CD19\/22 chimeric antigen receptor T-cell therapy for childhood refractory lupus nephritis. Kid. Int. Rep. 13, 53\u201361 (2025).","journal-title":"Kid. Int. Rep."},{"key":"4430_CR53","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine 69, 102476 (2024).","journal-title":"EClinicalMedicine"},{"key":"4430_CR54","doi-asserted-by":"publisher","first-page":"e005866","DOI":"10.1136\/rmdopen-2025-005866","volume":"11","author":"EWY Hsieh","year":"2025","unstructured":"Hsieh, E. W. Y. et al. Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective. RMD Open 11, e005866 (2025).","journal-title":"RMD Open"},{"key":"4430_CR55","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller, F. et al. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat. Med. 31, 1793\u20131797 (2025).","journal-title":"Nat. Med."},{"key":"4430_CR56","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187, 4890\u20134904 (2024).","journal-title":"Cell"},{"key":"4430_CR57","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell 188, 4225\u20134238 (2025).","journal-title":"Cell"},{"key":"4430_CR58","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3713\u20133724 (2025).","journal-title":"Nat. Med."},{"key":"4430_CR59","doi-asserted-by":"publisher","first-page":"100749","DOI":"10.1016\/j.medj.2025.100749","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med 6, 100749 (2025).","journal-title":"Med"},{"key":"4430_CR60","doi-asserted-by":"crossref","unstructured":"Gao, J. et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet 406, 2968\u20132979 (2026).","DOI":"10.1016\/S0140-6736(25)01671-X"},{"key":"4430_CR61","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4430_CR62","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142, 865\u2013877 (2023).","journal-title":"Blood"},{"key":"4430_CR63","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried, S. et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 54, 1643\u20131650 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"4430_CR64","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood.2025028375","volume":"146","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller, F. et al. Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood 146, 1088\u20131095 (2025).","journal-title":"Blood"},{"key":"4430_CR65","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen, M. et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 7, 424\u2013433 (2025).","journal-title":"Lancet Rheumatol."},{"key":"4430_CR66","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","volume":"77","author":"A Yafasova","year":"2021","unstructured":"Yafasova, A. et al. Long-term cardiovascular outcomes in systemic lupus erythematosus. J. Am. Coll. Cardiol. 77, 1717\u20131727 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4430_CR67","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/art.40079","volume":"69","author":"F Tamirou","year":"2017","unstructured":"Tamirou, F. et al. Brief Report: The Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone. Arthritis Rheumatol. 69, 1267\u20131271 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"4430_CR68","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"4430_CR69","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"4430_CR71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur, C. et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann. Rheum. Dis. 84, 106\u2013114 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR72","doi-asserted-by":"crossref","unstructured":"Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. 84, 2065\u20132074 (2025).","DOI":"10.1016\/j.ard.2025.06.2120"},{"key":"4430_CR73","doi-asserted-by":"publisher","first-page":"e179433","DOI":"10.1172\/jci.insight.179433","volume":"9","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm, A. et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight 9, e179433 (2024).","journal-title":"JCI Insight"},{"key":"4430_CR74","doi-asserted-by":"crossref","unstructured":"Garantziotis, P. et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann. Rheum. Dis. 85, 153\u2013163 (2025).","DOI":"10.1016\/j.ard.2025.06.2132"},{"key":"4430_CR75","doi-asserted-by":"crossref","unstructured":"Taubmann, J. et al. Effects of CD19 CAR T cell therapy on quality of life and direct healthcare costs in systemic lupus erythematosus: a preliminary analysis. J. Rheumatol. 53, 33\u201337 (2025).","DOI":"10.3899\/jrheum.2024-1301"},{"key":"4430_CR76","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"4430_CR77","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4430_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"4430_CR79","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","volume":"84","author":"Y Fu","year":"2025","unstructured":"Fu, Y. et al. Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 84, 1811\u20131821 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4430_CR80","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"35","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. 35, 220\u2013223 (2025).","journal-title":"Cell Res."},{"key":"4430_CR81","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.4049\/jimmunol.172.7.4298","volume":"172","author":"AJ Cappione","year":"2004","unstructured":"Cappione, A. J., Pugh-Bernard, A. E., Anolik, J. H. & Sanz, I. Lupus IgG VH4.34 antibodies bind to a 220\u2009kDa glycoform of CD45\/B220 on the surface of human B lymphocytes. J. Immunol. 172, 4298\u20134307 (2004).","journal-title":"J. Immunol."},{"key":"4430_CR82","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"4430_CR83","doi-asserted-by":"publisher","first-page":"eadr9382","DOI":"10.1126\/scitranslmed.adr9382","volume":"18","author":"IJ Cohen","year":"2026","unstructured":"Cohen, I. J. et al. Chimeric antigen receptor T cells against IGHV4-34 B cell receptor specifically eliminate neoplastc and autoimmune B cells. Sci. Transl. Med. 18, eadr9382 (2026).","journal-title":"Sci. Transl. Med."},{"key":"4430_CR84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"4430_CR85","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","volume":"29","author":"OV Britanova","year":"2023","unstructured":"Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731\u20132736 (2023).","journal-title":"Nat. Med."},{"key":"4430_CR86","doi-asserted-by":"publisher","first-page":"e167215","DOI":"10.1172\/jci.insight.167215","volume":"8","author":"I Rosado-S\u00e1nchez","year":"2023","unstructured":"Rosado-S\u00e1nchez, I. et al. Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection. JCI Insight 8, e167215 (2023).","journal-title":"JCI Insight"},{"key":"4430_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"4430_CR88","unstructured":"Kohler M., et al. A phase 1 study of autologous CAR-Treg cells in refractory rheumatoid arthritis: interim report of safety and efficacy. In ACR Convergence 2025 Abstract LB23 (ACR, 2025)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04430-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:07:30Z","timestamp":1781824050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04430-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4430"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04430-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S. received speaker honoraria from BMS, Cabaletta, Eli Lilly, Johnson & Johnson, Kyverna, Novartis, Orbital and UCB. H.X. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}